Publications by authors named "Miharu Suda"
Article Synopsis
- DS-5670 is an mRNA vaccine targeting the spike protein of SARS-CoV-2, showing safety and effectiveness in adults for COVID-19 booster vaccination.
- A study with children aged 5-11 years assessed a third booster of either DS-5670a/b or bivalent BNT162b2 after initial vaccination, measuring blood neutralization response to variants.
- Results indicated DS-5670a/b produced a comparable immune response to BNT162b2, exceeding safety benchmarks with no new safety concerns noted among the pediatric participants.
Background And Objectives: DS-1040 is a novel inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor that may have therapeutic potential in thromboembolic diseases, such as acute ischemic stroke (AIS) or pulmonary embolism. We undertook a Phase I clinical trial to investigate the safety, pharmacokinetics, and pharmacodynamics of DS-1040 in Japanese patients who were eligible for thrombectomy following AIS.
Methods: The trial enrolled patients with AIS due to large vessel occlusion, who were planned for thrombectomy within 8 h of symptom onset.